Your Tax Bill Wasn't Random- It Was a Strategy Gap
A $600K compensation package should feel like meaningful progress. For many pharmaceutical executives, it does not. The disconnect is rarely about spending. It is structural. Modern pharma compensation is layered, delayed, and often misunderstood. Between RSUs taxed as income, bonuses that are underwithheld, and equity that may never fully materialize, total compensation can create a misleading sense of financial security. This article outlines six structural reasons why high earners often overestimate what they actually keep, and why clarity around taxes, timing, and risk is essential for turning income into real flexibility.